

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA PIONEER PHARMA HOLDINGS LIMITED**

**中国先锋医药控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 01345)**

### **POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 30 SEPTEMBER 2022**

At the extraordinary general meeting (the “**EGM**”) of China Pioneer Pharma Holdings Limited (the “**Company**”) held on 30 September 2022, voting on the proposed resolution as set out in the notice of the EGM dated 8 September 2022 was taken by poll.

As at the date of the EGM, the total number of issued shares of the Company was 1,257,447,000 shares, which was the total number of shares entitling the holders to attend and vote on the resolution proposed at the EGM. There were no restrictions on any shareholders of the Company casting votes on the proposed resolution at the EGM. There are not any shareholders that have stated their intention in the circular of the Company dated 8 September 2022 to vote against or to abstain from voting on the resolution at the EGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the resolution proposed at the EGM were as follows:

SPECIAL RESOLUTION		Number of Votes (%)	
		For	Against
1.	That subject to and conditional upon the necessary approval of the Registrar of Companies in the Cayman Islands being obtained, the English name of the Company be changed from "China Pioneer Pharma Holdings Limited" to "Shanghai Pioneer Holding Ltd" and the dual foreign name of the Company in Chinese be changed from "中国先锋医药控股有限公司" to "上海先锋控股有限公司", and that the directors of the Company be and are hereby authorised to do all such acts, and execute such deeds and things they may, in their absolute discretion, deem fit in order to effect such change of name.	878,233,742 99.50%	4,402,000 0.50%

As more than 75% of votes were cast in favour of the resolution above, the above special resolution was approved by the shareholders of the Company.

The executive director, Mr. Yang Yuewen attended the EGM.

By order of the Board  
**China Pioneer Pharma Holdings Limited**  
**LI Xinzhou**  
*Chairman*

Shanghai, 30 September 2022

*As at the date of this announcement, Mr. LI Xinzhou, Mr. XIAO Guoguang and Mr. YANG Yuewen are as executive directors, Ms. HU Mingfei as a non-executive director and Mr. ZHANG Hong, Mr. WONG Chi Hung, Stanley and Mr. LAI Chanshu as independent non-executive directors.*